ETFs Holding OCUL »    OCUL Historical Stock Prices »
OCUL News Video: Tue, Jan 24, 2017, 1:31 PM — Tuesday Sector Laggards: Drugs, Waste Management Stocks

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Co.'s bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Co.'s key product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular pain, allergic conjunctivitis and dry eye disease; and OTX-TP, for the treatment of glaucoma and ocular hypertension. Co. also markets its commercial product, ReSure Sealant, a hydrogel-based ophthalmic wound sealant for ophthalmic use. Self directed investors in Ocular Therapeutix Inc will be interested in keeping up with all Ocular Therapeutix Inc news they can find, both OCUL news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on OCUL. At RediNews, we simplify this task by presenting both OCUL news releases originating from Ocular Therapeutix Inc itself, and OCUL news from a variety of media outlets. Visitors can browse this news online and through our OCUL RSS news feed.


OCUL News — Articles, Videos, & Press Releases

Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
Tuesday, May 21, 2019, 3:36 PM — Zacks
OCUL: Insiders vs. Shorts
Wednesday, May 15, 2019, 4:09 PM — Market News Video
First Week of December 20th Options Trading For Ocular Therapeutix (OCUL)
Tuesday, April 30, 2019, 10:38 AM — Stock Options Channel
Adding Up The Components: Russell 2000 Could Rise 15%
Wednesday, April 10, 2019, 7:57 AM — ETF Channel
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
Tuesday, March 26, 2019, 9:51 AM — Zacks
First Week of May 17th Options Trading For Ocular Therapeutix (OCUL)
Wednesday, March 20, 2019, 10:58 AM — Stock Options Channel
Surprising Analyst 12-Month Target For RYJ
Wednesday, March 6, 2019, 8:35 AM — ETF Channel
OCUL: Insiders vs. Shorts
Wednesday, February 13, 2019, 2:38 PM — Market News Video
Ocular Therapeutix Stock Sees Short Interest Make 14.6% Move
Tuesday, January 29, 2019, 3:00 PM — Market News Video
Peek Under The Hood: IBB Has 35% Upside
Tuesday, January 29, 2019, 8:03 AM — ETF Channel
Interesting OCUL Call Options For February 15th
Monday, January 7, 2019, 10:34 AM — Stock Options Channel
Russell 2000 Headed 35% Higher, If Analysts Got The Components Right
Friday, December 28, 2018, 9:50 AM — ETF Channel
Commit To Buy Ocular Therapeutix At $2.50, Earn 16.5% Annualized Using Options
Wednesday, December 26, 2018, 11:23 AM — Stock Options Channel
Noteworthy Monday Option Activity: OCUL, EDIT, FDX
Monday, December 3, 2018, 3:20 PM — Stock Options Channel
Ocular Therapeutix Breaks Above 200-Day Moving Average - Bullish for OCUL
Friday, November 30, 2018, 12:06 PM — Market News Video
OCUL: Insiders vs. Shorts
Wednesday, November 14, 2018, 2:17 PM — Market News Video
Relative Strength Alert For Ocular Therapeutix
Wednesday, October 24, 2018, 4:32 PM — Dividend Channel
Look Under The Hood: PXSG Has 33% Upside
Wednesday, October 24, 2018, 8:11 AM — ETF Channel
OCUL Makes Notable Cross Below Critical Moving Average
Friday, October 5, 2018, 12:56 PM — Market News Video
First Week of OCUL November 16th Options Trading
Thursday, September 27, 2018, 10:47 AM — Stock Options Channel
Top Buys by Top Brass: CEO Mattessich's $224.3K Bet on OCUL
Wednesday, August 22, 2018, 2:03 PM — Dividend Channel
OCUL: Insiders vs. Shorts
Thursday, August 16, 2018, 2:22 PM — Market News Video
OCUL Trading Below CEO's Recent Buy Price
Wednesday, August 15, 2018, 10:01 AM — Dividend Channel
Analysts Expect PXSG To Hit $46
Wednesday, August 15, 2018, 7:40 AM — ETF Channel
Interesting OCUL Put And Call Options For March 2019
Thursday, August 9, 2018, 10:40 AM — Stock Options Channel
Ocular Therapeutix is Now Oversold (OCUL)
Wednesday, July 25, 2018, 12:00 PM — Dividend Channel
OCUL Crosses Below Key Moving Average Level
Monday, July 23, 2018, 11:58 AM — Market News Video
Analysts Predict 16% Gains Ahead For PXSG
Thursday, July 12, 2018, 7:42 AM — ETF Channel
Ocular Therapeutix is Now Oversold (OCUL)
Monday, July 2, 2018, 12:05 PM — Dividend Channel
Notable Tuesday Option Activity: AAWW, KORS, OCUL
Tuesday, June 12, 2018, 3:19 PM — Stock Options Channel
OCUL is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


Anyone with a stock market portfolio cares about more than stock market price information, or the historical stock price of the stocks they own, or whether their stocks show up on the latest top ten stocks list. They also care about news. What news is coming out of the company, and, what are third party articles and videos saying? Your web site content may feature an excellent stock market screener and nice web page chart graphics, but if you are lacking in the news offerings you are missing a big reason for visitors to return to your site. People form habits, one of which is to check the weather forecast, another is to check the stock market price levels of the major indices, and a third is to check the news for their stocks they own. So don't pass up integrating our free RediNews RSS news feeds. Simply navigate to any RediNews news page by specific ticker symbol or by sector, then click the RSS icon for that news page to reach the associated RSS feed (the icon will look like this): .

OCUL News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.